SCHEMBL14728488

SCHEMBL14728488

N#Cc1c2c(c(N3CCCC3)n3c1nc1ccccc13)C1CCC2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 5/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
MAPK1 P28482 2/20 0.50
ALOX12 P18054 1/20 0.50
ALDH1A1 P00352 6/20 0.49
CASP1 P29466 5/20 0.49
HSD17B10 Q99714 5/20 0.49
TSHR P16473 4/20 0.49
CASP7 P55210 3/20 0.49
HPGD P15428 3/20 0.49
KDM4E B2RXH2 9/20 0.48
PKM P14618 1/20 0.48
RXFP1 Q9HBX9 3/20 0.48
CYP2C9 P11712 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
ATM Q13315 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HIF1A Q16665 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728490 0.90 MAPK1 (0.46) NPSR1MEN1KMT2AMAPK1ALOX12
SCHEMBL14728486 0.90 MAPK1 (0.46) NPSR1MEN1KMT2AMAPK1ALOX12
SCHEMBL14728489 0.90 ALDH1A1 (0.50) NPSR1MEN1KMT2AMAPK1ALOX12
SCHEMBL14728491 0.86 ALDH1A1 (0.45) NPSR1MEN1KMT2AMAPK1ALOX12
SCHEMBL14728575 0.84 KDM4E (0.46) NPSR1MEN1KMT2AMAPK1ALOX12
SCHEMBL14728265 0.81 NPSR1 (0.53) NPSR1MEN1KMT2AALDH1A1TSHR
SCHEMBL14728580 0.80 NPSR1 (0.56) NPSR1MEN1KMT2AMAPK1ALOX12
SCHEMBL14728424 0.80 NPSR1 (0.56) NPSR1MEN1KMT2AMAPK1ALOX12
SCHEMBL14728469 0.79 NPSR1 (0.55) NPSR1MEN1KMT2AMAPK1ALOX12
SCHEMBL14728456 0.77 NPSR1 (0.55) NPSR1MEN1KMT2AMAPK1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE PDE4B, PDE4A, PDE4C NPSR1 2690/4885MEN1 4281/4885KMT2A 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.